Current Antiretroviral Therapies and Future Trends in Management of Human Immunodeficiency Virus-1 Infection

被引：0

作者：

Bulteel, Naomi S. ^{[1
]}

Leen, Clifford ^{[1
]}

机构：

[1] Western Gen Hosp, Reg Infect Dis Unit, Edinburgh, Midlothian, Scotland

来源：

ERCIYES MEDICAL JOURNAL | 2019年 / 41卷 / 01期

关键词：

HIV; AIDS; antiretroviral therapy; PROTEASE INHIBITOR MONOTHERAPY; RITONAVIR PLUS LAMIVUDINE; REVERSE-TRANSCRIPTASE INHIBITORS; TENOFOVIR DISOPROXIL FUMARATE; ONCE-DAILY MARAVIROC; OPEN-LABEL; NON-INFERIORITY; HIV-1; INFECTION; DUAL THERAPY; TRIPLE THERAPY;

D O I：

10.14744/etd.2019.19210

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Earlier initiation of antiretroviral therapy (ART) for human immunodeficiency virus (HIV)-1 infection is associated with reduced HIV-related morbidity and mortality, improved immune recovery, and reduced risk of HIV-1 transmission. Consequently, international guidelines now recommend ART for all HIV-1-infected adults, regardless of CD4 cell count. The shift in guidance has led to concern regarding long-term ART toxicity, and new strategies to limit ART exposure have been proposed. In this review, we will discuss current recommendations for ART and future trends in management including mono- and dual-therapy, new ART formulations, and novel antiretroviral agents.

引用

页码：5 / 11

页数：7

共 41 条

[1]

[Anonymous], GUID US ANT AG AD AD

[2]

[Anonymous], GLASG HIV C 2018 28

[3]

[Anonymous], BRIT HIV ASS GUIDELI

[4] Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial [J].

Arribas, Jose R. ;

Girard, Pierre-Marie ;

Landman, Roland ;

Pich, Judit ;

Mallolas, Josep ;

Martinez-Rebollar, Maria ;

Zamora, Francisco X. ;

Estrada, Vicente ;

Crespo, Manuel ;

Podzamczer, Daniel ;

Portilla, Joaquin ;

Dronda, Fernando ;

Iribarren, Jose A. ;

Domingo, Pere ;

Pulido, Federico ;

Montero, Marta ;

Knobel, Hernando ;

Cabie, Andre ;

Weiss, Laurence ;

Gatell, Jose M. .

LANCET INFECTIOUS DISEASES, 2015, 15 (07) :785-792

[5] The RADAR Study: Week 48 Safety and Efficacy of RAltegravir Combined with Boosted DARunavir Compared to Tenofovir/Emtricitabine Combined with Boosted Darunavir in Antiretroviral-Naive Patients. Impact on Bone Health [J].

Bedimo, Roger J. ;

Drechsler, Henning ;

Jain, Mamta ;

Cutrell, James ;

Zhang, Song ;

Li, Xilong ;

Farukhi, Irfan ;

Castanon, Rosinda ;

Tebas, Pablo ;

Maalouf, Naim M. .

PLOS ONE, 2014, 9 (08)

[6] Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials [J].

Cahn, Pedro ;

Sierra Madero, Juan ;

Ramon Arribas, Jose ;

Antinori, Andrea ;

Ortiz, Roberto ;

Clarke, Amanda E. ;

Hung, Chien-Ching ;

Rockstroh, Jurgen K. ;

Girard, Pierre-Marie ;

Sievers, Jorg ;

Man, Choy ;

Currie, Alexander ;

Underwood, Mark ;

Tenorio, Allan R. ;

Pappa, Keith ;

Wynne, Brian ;

Fettiplace, Anna ;

Gartland, Martin ;

Aboud, Michael ;

Smith, Kimberly .

LANCET, 2019, 393 (10167) :143-155

[7] Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study [J].

Cahn, Pedro ;

Rolon, Maria Jose ;

Figueroa, Maria Ines ;

Gun, Ana ;

Patterson, Patricia ;

Sued, Omar .

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2017, 20

[8] Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviraltherapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial [J].

Cahn, Pedro ;

Andrade-Villanueva, Jaime ;

Arribas, Jose R. ;

Gatell, Jose M. ;

Lama, Jiavier R. ;

Norton, Michael ;

Patterson, Patricia ;

Sierra Madero, Juan ;

Sued, Omar ;

Ines Figueroa, Maria ;

Jose Rolon, Maria .

LANCET INFECTIOUS DISEASES, 2014, 14 (07) :572-580

[9] Protease Inhibitor Monotherapy as Maintenance Regimen in Patients With HIV Infection [J].

Calza, Leonardo ;

Manfredi, Roberto .

CURRENT HIV RESEARCH, 2012, 10 (08) :661-672

[10] Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial [J].

Ciaffi, Laura ;

Koulla-Shiro, Sinata ;

Sawadogo, Adrien Bruno ;

Ndour, Cheik Tidiane ;

Eymard-Duvernay, Sabrina ;

Mbouyap, Pretty Rosereine ;

Ayangma, Liliane ;

Zoungrana, Jacques ;

Gueye, Ndeye Fatou Ngom ;

Diallo, Mohamadou ;

Izard, Suzanne ;

Bado, Guillaume ;

Kane, Coumba Toure ;

Aghokeng, Avelin Fobang ;

Peeters, Martine ;

Girard, Pierre Marie ;

Le Moing, Vincent ;

Reynes, Jacques ;

Delaporte, Eric .

LANCET HIV, 2017, 4 (09) :E384-E392

← 1 2 3 4 5 →